Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
1. A composition for increasing phagocytosis of a target cell, the composition comprising:
(a) an antibody that specifically binds to leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and does not activate signaling through LILRB1 upon binding; and (b) an agent an antibody that binds to the target cell and thereby opsonizes the target cell.
2. The composition of claim 1 , wherein the composition further comprises an anti-CD47/signal regulatory protein alpha (SIRPA) agent.
3. The composition according to claim 1 , wherein the antibody that binds to the target cell binds to CD20.
4. The composition according to claim 3 , wherein the antibody is rituximab.
5. The composition according to claim 1 , wherein the antibody that binds to the target cell binds to EGFR.
6. The composition according to claim 5 , wherein the antibody is cetuximab.
7. A method of inducing phagocytosis of a target cell, the method comprising:
contacting a target cell with a macrophage in the presence of an antibody that specifically binds to leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and does not activate signaling through LILRB1 upon binding and an antibody that binds to the target cell and thereby opsonizes the target cell, for a period of time sufficient to induce phagocytosis of the target cell by the macrophage.
8. The method according to claim 7 , wherein the target cell is a cancer cell.
9. The method according to claim 7 , wherein the target cell is a cell infected with an intracellular pathogen.
10. The method according to claim 7 , wherein the target cell is a cancer cell of an individual having cancer, or an infected cell of an individual having a chronic intracellular pathogen infection.
11. The method according to claim 7 , wherein the contacting is in vitro or ex vivo.
12. The method according to claim 7 , wherein the contacting is in vivo.
13. The method according to claim 7 , wherein said contacting is in the presence of an antibody that specifically binds to CD47 and blocks interaction of CD47 and SIRPα.
14. The method according to claim 7 , wherein the antibody that binds to the target cell binds to CD20.
15. The method according to claim 14 , wherein the antibody is rituximab.
16. The method according to claim 7 , wherein the antibody that binds to the target cell binds to EGFR.
17. The method according to claim 16 , wherein the antibody is cetuximab.